CX Institutional
MDGL icon

CX Institutional’s Madrigal Pharmaceuticals MDGL Stock Holding History

CX Institutional’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1K Hold
2
– – ﹤0.01% 1634
2026
Q2 		$1K Hold
2
– – ﹤0.01% 1534
2026
Q1 		$1K Hold
2
– – ﹤0.01% 1519
2025
Q4 		$1K Buy
+2
New +$1.02K ﹤0.01% 1472

Other funds holding MDGL

EULAV Asset Management
EULAV Asset Management Sarasota, Florida $2.77B AUM 18.47% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bourgeon Capital Management
Bourgeon Capital Management Darien, Connecticut $696M AUM 39.92% 1-Year Est. Return
Shikiar Asset Management
Shikiar Asset Management New York $398M AUM 33.64% 1-Year Est. Return
Stanley-Laman Group
Stanley-Laman Group Berwyn, Pennsylvania $915M AUM 50.26% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
BI Asset Management Fondsmaeglerselskab
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

CX Institutional's MDGL Position: Q3 2026 in Review

CX Institutional held its Madrigal Pharmaceuticals (MDGL) position steady in Q3 2026 at 2 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1634.

CX Institutional first reported a position in MDGL in Q4 2025 and has held it in 4 quarters since. 67 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • CX Institutional held 2 shares of Madrigal Pharmaceuticals worth $1K as of Q3 2026.
  • CX Institutional left its Madrigal Pharmaceuticals share count unchanged in Q3 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of CX Institutional's portfolio in Q3 2026, its #1634 holding.
  • CX Institutional first reported a position in Madrigal Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • 67 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on CX Institutional's 13F filing for Q3 2026, filed 2 Oct 2026.